Mantle Cell Lymphoma

Praveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

The FDA has granted a priority review designation to a biologics license application for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the immunologic impact of long-term venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

David Ritchie, MD, PhD, discusses the long-term immunological response to the combination of venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the utility of novel agents in mantle cell lymphoma (MCL).

The European Medicines Agency has validated and is now evaluating a Marketing Authorization Application for the CAR T-cell therapy KTE-X19 for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

Praveen Ramakrishnan, MD, discusses the benefit of CAR T-cell therapy in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.